Informationen: Dieses ist nicht die aktuellste Version des Datenmodells. Eine Versionsübersicht finden Sie links unter Versionen. Die aktuellste Version finden Sie hier.
Informationen:
Fehler:
ID
37860
Beschreibung
Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01153282
Link
https://clinicaltrials.gov/show/NCT01153282
Stichworte
Versionen (2)
- 28.08.19 28.08.19 -
- 28.08.19 28.08.19 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
28. August 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Breast Cancer NCT01153282
Eligibility Breast Cancer NCT01153282
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Breast Cancer NCT01153282
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Gender | Age
Item
women 21-70 years old (women over 70 are offered chemotherapy less frequently because of their risk benefit ratio. including them would be a selection bias because of their differential underexposure).
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0001779 (UMLS CUI [2])
Taxane | Neoadjuvant Chemotherapy | Chemotherapy, Adjuvant | Neoplasm Metastasis Untreated
Item
initiated taxane-based chemotherapy in the neoadjuvant, adjuvant, or previously untreated metastatic setting.
boolean
C0215136 (UMLS CUI [1])
C0600558 (UMLS CUI [2,1])
C3665472 (UMLS CUI [2,2])
C0085533 (UMLS CUI [3])
C0027627 (UMLS CUI [4,1])
C0332155 (UMLS CUI [4,2])
C0600558 (UMLS CUI [2,1])
C3665472 (UMLS CUI [2,2])
C0085533 (UMLS CUI [3])
C0027627 (UMLS CUI [4,1])
C0332155 (UMLS CUI [4,2])
Exposure to Taxane Chemotherapy | Chemotherapy cycle Quantity | Timespan Infusion Last
Item
the range of exposure to taxane-based chemotherapy will include women on active treatment having received two cycles, to women who are within three months of their last infusion.
boolean
C0332157 (UMLS CUI [1,1])
C0215136 (UMLS CUI [1,2])
C3665472 (UMLS CUI [1,3])
C1302181 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0872291 (UMLS CUI [3,1])
C0574032 (UMLS CUI [3,2])
C1517741 (UMLS CUI [3,3])
C0215136 (UMLS CUI [1,2])
C3665472 (UMLS CUI [1,3])
C1302181 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0872291 (UMLS CUI [3,1])
C0574032 (UMLS CUI [3,2])
C1517741 (UMLS CUI [3,3])
ID.4
Item
documented symptoms of cipn per ctcae grading criteria (half of sample) or no symptoms (half of sample) grade 0 = no cipn symptoms grade 1 = mild symptoms grade 2 = moderate symptoms - prescribed gabapentin (neurontin) grade 3&4= severe symptoms -
boolean
Gabapentin | Neurontin | Treatment Plan altered
Item
treated with gabapentin (neurontin), treatment plan altered
boolean
C0060926 (UMLS CUI [1])
C0678176 (UMLS CUI [2])
C0599880 (UMLS CUI [3,1])
C0392747 (UMLS CUI [3,2])
C0678176 (UMLS CUI [2])
C0599880 (UMLS CUI [3,1])
C0392747 (UMLS CUI [3,2])
Physical disability | Use of Assistive Devices | Wheelchair | Crutches | Limb Prosthesis
Item
physical disabilities - defined by use of assistive devices to complete functional tasks (wheelchair, crutches, prosthetic limbs) prior to starting chemotherapy.
boolean
C0520817 (UMLS CUI [1])
C1524063 (UMLS CUI [2,1])
C0036605 (UMLS CUI [2,2])
C0043143 (UMLS CUI [3])
C0010397 (UMLS CUI [4])
C0347948 (UMLS CUI [5])
C1524063 (UMLS CUI [2,1])
C0036605 (UMLS CUI [2,2])
C0043143 (UMLS CUI [3])
C0010397 (UMLS CUI [4])
C0347948 (UMLS CUI [5])
Exposure to Neurotoxic agents | Navelbine | Platinum | Taxanes
Item
current exposure to neurotoxic agents (navelbine, platinums or other taxanes)
boolean
C0332157 (UMLS CUI [1,1])
C0260049 (UMLS CUI [1,2])
C0131965 (UMLS CUI [2])
C0032207 (UMLS CUI [3])
C0796419 (UMLS CUI [4])
C0260049 (UMLS CUI [1,2])
C0131965 (UMLS CUI [2])
C0032207 (UMLS CUI [3])
C0796419 (UMLS CUI [4])
Pregnancy During Chemotherapy
Item
pregnancy during chemotherapy treatment
boolean
C0032961 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
C0347984 (UMLS CUI [1,2])
C0392920 (UMLS CUI [1,3])
Diabetes Mellitus Disease length | Diabetes Mellitus, Insulin-Dependent | Diabetes Mellitus With Neuropathy
Item
diabetes - diagnosed 3 or more years , or insulin dependent, or with clinically established neuropathy
boolean
C0011849 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
C0011854 (UMLS CUI [2])
C0011849 (UMLS CUI [3,1])
C0332287 (UMLS CUI [3,2])
C0442874 (UMLS CUI [3,3])
C0872146 (UMLS CUI [1,2])
C0011854 (UMLS CUI [2])
C0011849 (UMLS CUI [3,1])
C0332287 (UMLS CUI [3,2])
C0442874 (UMLS CUI [3,3])
Exposure to Chemotherapy | Exposure to Therapeutic radiology procedure
Item
previous exposure to chemotherapy or radiotherapy
boolean
C0332157 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
C0392920 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C1522449 (UMLS CUI [2,2])
HIV Seropositivity | High risk of Neuropathy
Item
hiv positive (high risk for neuropathy)
boolean
C0019699 (UMLS CUI [1])
C0332167 (UMLS CUI [2,1])
C0442874 (UMLS CUI [2,2])
C0332167 (UMLS CUI [2,1])
C0442874 (UMLS CUI [2,2])
Nervous system disorder | Multiple Sclerosis
Item
other neurological diseases, such as multiple sclerosis
boolean
C0027765 (UMLS CUI [1])
C0026769 (UMLS CUI [2])
C0026769 (UMLS CUI [2])
Neuropathy Pre-existing
Item
other pre-existing neuropathy
boolean
C0442874 (UMLS CUI [1,1])
C2347662 (UMLS CUI [1,2])
C2347662 (UMLS CUI [1,2])